Predictors of pathologic complete response after preoperative concurrent chemoradiotherapy of rectal cancer: a single center experience

다국어 초록 (Multilingual Abstract)

Purpose: To identify possible predictors of pathologic complete response (pCR) of rectal cancer after preoperative concurrent chemoradiotherapy (CCRT).
Materials and Methods: We conducted a retrospective review of 53 patients with rectal cancer who underwent preoperative CCRT followed by radical surgery at a single center between January 2007 and December 2012. The median radiotherapy dose to the pelvis was 54.0 Gy (range, 45.0 to 63.0 Gy). Five-fluorouracil-based chemotherapy was administered via continuous infusion with leucovorin.
Results: The pCR rate was 20.8%. The downstaging rate was 66%. In univariate analyses, poor and undifferentiated tumors (p = 0.020) and an interval of ≥7 weeks from finishing CCRT to surgery (p = 0.040) were significantly associated with pCR, while female gender (p = 0.070), initial carcinoembryonic antigen concentration of <5.0 ng/dL (p = 0.100), and clinical stage T2 (p = 0.100) were marginally significant factors. In multivariate analysis, an interval of ≥7 weeks from finishing CCRT to surgery (odds ratio, 0.139; 95% confidence interval, 0.022 to 0.877; p = 0.036) was significantly associated with pCR, while stage T2 (odds ratio, 5.363; 95% confidence interval, 0.963 to 29.877; p = 0.055) was a marginally significant risk factor.
Conclusion: We suggest that the interval from finishing CCRT to surgery is a predictor of pCR after preoperative CCRT in patients with rectal cancer. Stage T2 cancer may also be an important predictive factor. We hope to perform a robust study by collecting data during treatment to obtain more advanced results.

참고문헌 (Reference)

1 Lambrecht M, "Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results" 82 : 863-870, 2012

2 Park JH, "Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer" 117 : 3703-3712, 2011

3 Sauer R, "Preoperative versus postoperative chemoradiotherapy for rectal cancer" 351 : 1731-1740, 2004

4 Gerard JP, "Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203" 24 : 4620-4625, 2006

5 Kapiteijn E, "Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer" 345 : 638-646, 2001

6 Roh MS, "Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03" 27 : 5124-5130, 2009

7 Das P, "Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer" 109 : 1750-1755, 2007

8 Kim JW, "Predictive value of (18)FDG PET-CT for tumour response in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy" 28 : 1217-1224, 2013

9 Rodel C, "Predictive significance of tumor regression after preoperative chemoradiotherapy for rectal cancer" 23 : 8688-8696, 2005

10 Carlomagno C, "Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer" 78 : 369-375, 2010

11 Crucitti F, "Predictive factors in colorectal cancer: current status and new trends" 2 : 76-82, 1991

12 Shanmugan S, "Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT" 19 : 2178-2185, 2012

13 Chen MB, "P53 status as a predictive biomarker for patients receiving neoadjuvant radiationbased treatment: a meta-analysis in rectal cancer" 7 : e45388-, 2012

14 Sasaki O, "Mucinous carcinoma of the rectum" 11 : 259-272, 1987

15 Maas M, "Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data" 11 : 835-844, 2010

16 Pettersson D, "Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer" 97 : 580-587, 2010

17 Latkauskas T, "Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed surgery" 14 : 294-298, 2012

18 Wolthuis AM, "Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome" 19 : 2833-2841, 2012

19 Gunderson LL, "Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis" 22 : 1785-1796, 2004

20 Restivo A, "Elevated CEA levels and low distance of the tumor from the anal verge are predictors of incomplete response to chemoradiation in patients with rectal cancer" 20 : 864-871, 2013

21 Quirke P, "Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial" 373 : 821-828, 2009

22 Huh JW, "Clinical prediction of pathological complete response after preoperative chemoradiotherapy for rectal cancer" 56 : 698-703, 2013

23 Bosset JF, "Chemotherapy with preoperative radiotherapy in rectal cancer" 355 : 1114-1123, 2006

24 Khan AA, "Association between pretreatment haemoglobin levels and morphometric characteristics of the tumour, response to neoadjuvant treatment and long-term outcomes in patients with locally advanced rectal cancers" 15 : 1232-1237, 2013

25 Korea Central Cancer Registry, "Annual report of cancer statistics in Korea in 2010" Korea Central Cancer Registry 2012

26 Krauthamer M, "A study of inflammation-based predictors of tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer" 85 : 27-32, 2013